Product Details

Uniprot No.

Target Names

Alternative Names

Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform (PI3-kinase subunit alpha) (PI3K-alpha) (PI3Kalpha) (PtdIns-3-kinase subunit alpha) (EC 2.7.1.153) (Phosphatidylinositol 4,5-bisphosphate 3-kinase 110 kDa catalytic subunit alpha) (PtdIns-3-kinase subunit p110-alpha) (p110alpha) (Phosphoinositide-3-kinase catalytic alpha polypeptide) (Serine/threonine protein kinase PIK3CA) (EC 2.7.11.1), PIK3CA

Species Reactivity

Human, Mouse

Immunogen

A synthesized peptide derived from human PI 3 Kinase catalytic subunit alpha

Immunogen Species

Homo sapiens (Human)

Conjugate

Non-conjugated

Clonality

Monoclonal

Isotype

Rabbit IgG

Clone No.

10E5

Purification Method

Affinity-chromatography

Concentration

It differs from different batches. Please contact us to confirm it.

Buffer

Rabbit IgG in 10mM phosphate buffered saline , pH 7.4, 150mM sodium chloride, 0.05% BSA, 0.02% sodium azide and 50% glycerol.

Form

Liquid

Tested Applications

ELISA, WB, IF

Recommended Dilution

Application	Recommended Dilution
WB	1:500-1:5000
IF	1:20-1:200

Protocols

ELISA Protocol
Western Blotting(WB) Protocol
Immunofluorescence (IF) Protocol

Troubleshooting and FAQs

Antibody FAQs

Storage

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Lead Time

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

Description

PIK3CA, the catalytic alpha subunit of phosphatidylinositol 3-kinase, serves as a central node in the PI3K/AKT signaling pathway that governs cell growth, proliferation, and survival. As one of the most frequently mutated genes across human cancers, PIK3CA has become an essential target for researchers investigating oncogenic signaling mechanisms and therapeutic intervention strategies.

This recombinant monoclonal antibody, generated against a synthetic peptide derived from human PI 3 Kinase catalytic subunit alpha, offers the reproducibility and consistency that demanding experimental workflows require. Because the antibody sequence is defined and production occurs in a controlled recombinant system, you can expect reliable performance across experiments and between lots, eliminating a common source of variability in long-term studies.

Western blot validation demonstrates robust detection across an extensive panel of cell lines, including Jurkat, HepG2, HeLa, NIH/3T3, K562, 293, and MCF-7 lysates, confirming cross-species reactivity with both human and mouse samples. The observed band at approximately 110 kDa, slightly below the predicted 125 kDa molecular weight, likely reflects post-translational processing or conformational factors affecting migration. Immunofluorescence studies in HeLa cells reveal clear cytoplasmic localization patterns, enabling visualization of PIK3CA distribution within intact cellular architecture.

The antibody's compatibility with western blotting, immunofluorescence, and ELISA provides flexibility for researchers approaching PIK3CA biology from multiple angles, whether quantifying expression changes, examining subcellular localization, or developing screening assays. For investigators exploring cancer biology, immune cell signaling, or broader signal transduction questions, this antibody delivers the specificity and validation data needed to move projects forward with confidence.

Usage

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

Related Products

Target Background

Function

Phosphoinositide-3-kinase (PI3K) phosphorylates phosphatidylinositol (PI) and its phosphorylated derivatives at position 3 of the inositol ring to produce 3-phosphoinositides. Uses ATP and PtdIns(4,5)P2 (phosphatidylinositol 4,5-bisphosphate) to generate phosphatidylinositol 3,4,5-trisphosphate (PIP3). PIP3 plays a key role by recruiting PH domain-containing proteins to the membrane, including AKT1 and PDPK1, activating signaling cascades involved in cell growth, survival, proliferation, motility and morphology. Participates in cellular signaling in response to various growth factors. Involved in the activation of AKT1 upon stimulation by receptor tyrosine kinases ligands such as EGF, insulin, IGF1, VEGFA and PDGF. Involved in signaling via insulin-receptor substrate (IRS) proteins. Essential in endothelial cell migration during vascular development through VEGFA signaling, possibly by regulating RhoA activity. Required for lymphatic vasculature development, possibly by binding to RAS and by activation by EGF and FGF2, but not by PDGF. Regulates invadopodia formation through the PDPK1-AKT1 pathway. Participates in cardiomyogenesis in embryonic stem cells through a AKT1 pathway. Participates in vasculogenesis in embryonic stem cells through PDK1 and protein kinase C pathway. In addition to its lipid kinase activity, it displays a serine-protein kinase activity that results in the autophosphorylation of the p85alpha regulatory subunit as well as phosphorylation of other proteins such as 4EBP1, H-Ras, the IL-3 beta c receptor and possibly others. Plays a role in the positive regulation of phagocytosis and pinocytosis.

Gene References into Functions

We identified a total of five distinct mutations in PIK3CA (NM_006218.2), including one hotspot mutation (c.1624G>A;p.Glu542Lys); two recurrent, strong (gain of function) mutations (c.3140A>T;p.His1047Leu, c.1258T>C;p.Cys420Arg); one previously described mutation in patients with macrodactyly (c.344G>C;p.Arg115Pro); and one novel somatic PIK3CA mutation (c.248T>C; p.Phe83Ser) not previously described PMID: 29446767
PIK3CA mutation in gastric cancer is a rare finding. It is strongly associated with the microsatellite instability (MSI) molecular subgroup, presenting a worse outcome than other MSI patients. A completely different outcome is associated with the mutation in exon 9 compared to the mutation in exon 20, with the latter being more favorable. PMID: 29905413
In early breast cancer, PIK3CA mutations seem to identify HER2+ patients who are less likely to reach pCR. The clinical implications of PIK3CA mutations tend to vary between exon 9 and exon 20. This mechanism should be explored in further studies. PMID: 29575819
miR152 may have an important role in pancreatic beta cell function, and established an association between miR152 and the PI3Kalpha axis. PMID: 30106118
The majority of PIK3CA H1047R mutations in the breast cancer cohort precede genome doubling. PMID: 29170395
in Stage I colorectal cancer presence of KRAS mutations, that of simultaneous mutations in PIK3CA gene, or that of multiple KRAS mutations was significantly associated with shorter cancer specific survival; PIK3CA or multiple KRAS mutations were associated with nodal micrometastases and poorly differentiated clusters G3 as well PMID: 30018674
CTNNB1 mutations were found in 60% of Basal cell adenoma but not in basal cell adenocarcinoma. None of the tested cases had PIK3CA mutations. CTNNB1 mutation trended to be more common in those cases having a predominant tubular or tubulotrabecular patterns. PMID: 29224720
The crucial role of p110beta and the more subtle role of p110alpha in the production of PIP3 molecular species following platelet stimulation has been demonstrated. PMID: 29902570
High PI3K expression is associated with metastasis in ovarian cancer. PMID: 29739299
phenotypic changes in metabolism following a single copy knock-in of mutant PIK3CA (H1047R) in the MCF10A cell line, an important cell model for studying oncogenic transformation in breast tissues, were examined. PMID: 28393905
The PIK3CA and PIK3R1 impactful mutations exhibit a mutually exclusive pattern, leading to oncogenesis and hyperactivity of PI3K pathway in breast cancer. PMID: 29636477
PIK3CA mutation is associated with decreased risk of peritoneal metastases in chemo-resistant metastatic colorectal cancer. PMID: 29380640
High PIK3CA expression is associated with metastasis via epithelialmesenchymal transition carcinoma in colorectal cancer. PMID: 30066935
High expression of PI3KCA is associated with drug resistance and proliferation of breast cancer. PMID: 28165066
High PI3K expression is associated with periodontitis. PMID: 30218719
We validated the presence of IDH2 R172 hotspot mutations and PIK3CA hotspot mutations in 100% and 67% of solid papillary breast carcinoma with reverse polarity tested, respectively PMID: 29603332
High PIK3CA expression is associated with metastasis in colon cancer. PMID: 29305742
In this study, we used the Ion Personal Genome Machine (PGM) and Ion Torrent Ampliseq Cancer panel to sequence hotspot regions from PIK3CA, AKT and PTEN genes to identify genetic mutations in 39 samples of TNBC subtype from Moroccan patients and to correlate the results with clinical-pathologic data PMID: 30227836
Our results indicate that low-grade adenosquamous carcinoma of the breast of the breast is a low-grade triple-negative breast cancer that harbours a basal-like phenotype with no androgen receptor expression, and shows a high rate of PIK3CA mutations PMID: 29537649
Multivariate analyses revealed that the PIK3CA mutation and clinical T stage were independent favorable prognostic factors (hazard ratio 0.34, 95% confidence interval: 0.12-0.96, p = 0.042). PIK3CA mutations were significantly associated with APC alterations (p = 0.0007) and BRAF mutations (p = 0.0090). PMID: 30115035
higher frequency of ESR1 and PIK3CA mutations in the plasma than in the serum in 33 MBC patients; therefore, serum samples should not be considered the preferred source of cfDNA. PMID: 29689710
When considered together (43 cases), 1/25 cases (4%) with a PIK3CA mutation and/or low PTEN expression levels had a pathologic complete response (pCR)compared to 7/18 cases (39%) with wild-type PI3KCA and high PTEN expression levels (p = 0.006). PMID: 29110152
PI3K is a signal linker between L-selectin and PSGL-1 in IL-18 transcriptional activation at the promoter level. PMID: 29218606
The role of PI3K in cancer has been well established, and mutations of PIK3CA, the gene coding for catalytic subunit p110alpha of PI3K, are found in approximately 30% human cancers. we review the structures and activation modes of PI3Ks and its implications in angiogenesis, extracellular matrix remodeling and tumor immunity. PMID: 29219001
Double mutation of PIK3CA and TP53 is an independent predictive factor for overall survival in stage II/III colorectal cancer patients receiving 5-FU-based chemotherapy. PMID: 29434452
High PI3K expression is associated with cervical cancer. PMID: 29328485
High PIK3CA expression is associated with head and neck carcinoma. PMID: 29506489
pK15-dependent signaling may occur from intracellular vesicles and rely on the endocytotic machinery. Specifically, a class II PI3K, PI3K-C2alpha, is recruited by pK15 and involved in pK15-dependent intracellular signaling and viral reactivation from latency. PMID: 29950425
The data establish oncogenic PIK3CA mutations as a cause of glutamine dependency in colorectal cancer and suggest that targeting glutamine metabolism may be an effective approach to treat patients harboring PIK3CA mutations. PMID: 27321283
High Resolution Melting Analysis can be used as a rapid and sensitive method for mutation screening. Dysregulation of PIK3CA gene in bladder cancer reveals its potentials as a mechanistic link for cancer development, which in turn suggests its special use in interventional studies for targeted therapy PMID: 29353467
In patients without PIK3CA alteration, TP53 nonfunctional mutations are associated with poor prognosis. PMID: 29714670
Knowing the mutation status of KRAS, BRAF or PIK3CA in stage II colorectal cancer can significantly improve the accuracy of prognoses. PMID: 28685592
Survival analyses revealed that PIK3CA mutation was a significant prognostic factor for poor overall survival [multivariate adjusted hazard ratio (HR), 3.9; 95% confidence interval (95% CI), 1.3-11.8; P = .017] and cancer-specific survival (multivariate adjusted HR, 3.6; 95% CI, 1.2-11.0; P = .024) in stage IIB to IVA cervical cancers treated by concurrent chemoradiotherapy with weekly cisplatin. PMID: 30075505
Oncogenic PIK3CA alters methionine and cysteine utilization, partly by inhibiting xCT to contribute to the methionine dependency phenotype in human breast cancer cells. PMID: 29259101
The bladder cancer cell line TCCSUP, which harbors a PIK3CA E545K mutation, was sensitive to pictilisib compared to cell lines with wild-type PIK3CA Pictilisib exhibited stronger antitumor activity in bladder cancer patient-derived xenografts models with PI3KCA H1047R mutation or amplification than the control patient-derived xenografts model PMID: 28808038
By monitoring single-cell dynamics in each of these contexts, the authors identified PI3K/Akt regulation of glycolysis as a multifaceted modulator of single-cell metabolic dynamics that is required to maintain metabolic stability in proliferating cells. PMID: 29239720
results suggest that c-Jun, p38 MAPK, PIK3CA/Akt, and GSK3 signaling involved in the effect of miR-203 on the proliferation of hepatocellular carcinoma cells. PMID: 28887744
these results suggest that aspirin inhibited human uterine leiomyoma cell growth by regulating KRasp110alpha interaction. Aspirin which targeting on interaction between K-Ras and p110alpha may serve as a new therapeutic drug for uterine leiomyoma treatment. PMID: 28849118
PIK3CA mutation is a distinctive genetic feature of NSCLC with COPD, regardless of age, smoking dose, pathological stage, and histology. PMID: 29191607
In this study of 71 patients with advanced solid tumors who had received prior treatments (86% of whom were PIK3CA mutated), 3 different dose schedules of TAK-117 were evaluated. The MTD of TAK-117 was established as 150 mg once daily and 900 mg for both intermittent (MWF/MTuW) schedules. PMID: 28490463
Results show that head and neck squamous cell carcinoma tumors with low P120CTN and PI3K pathway mutations have higher levels of MMP1 compared to tumors with high P120CTN and no PI3K pathway mutations demonstrating that P120CTN downregulation and PIK3CA mutations promote MMP1-driven invasion. PMID: 28637905
Case Reports: PIK3CA mutations are present in multiple tissues of facial infiltrating lipomatosis. PMID: 28665924
p85alpha plays a tumor-suppressive role in transformation; p110alpha-selective therapeutics may be effective in the treatment of breast cancer patients with PIK3R1 loss PMID: 28630349
High Expressions of PI3K is associated with metastasis of esophageal squamous cell carcinoma. PMID: 28418888
E545K missense mutation of PIK3CA is associated with loss of protein stability and development of breast cancer. PMID: 27581627
while telomere length did not correlate with the presence of a mutation in BRAF (V-raf murine sarcoma viral oncogene homolog B), PIK3CA (phosphatidylinositol 3-kinase catalytic subunit), or MSI status, it was significantly associated with the occurrence of a mutation in KRAS PMID: 28850092
The combination of SAR256212 and SAR245408 resulted in stable disease as the best response. Side effects seen in combination were similar to the profiles of each individual drug. Patient outcome was the same regardless of tumor PI3KCA mutation status PMID: 28031425
High expression of PI3K is associated with nasopharyngeal carcinoma. PMID: 28586035
Study showed for the first time that co-occuring oncogenic HER2 and mutant PIK3CA could induce replication stress in mammary epithelial cells and drives breast cancer progression. PMID: 28902361
Mosaic gain of function mutation in PIK3CA gene leads to abnormal AKT-mTOR pathway activation and is responsible of the clinical manifestations. PMID: 28577738

Hide All

Involvement in disease

Colorectal cancer (CRC); Breast cancer (BC); Ovarian cancer (OC); Hepatocellular carcinoma (HCC); Keratosis, seborrheic (KERSEB); Megalencephaly-capillary malformation-polymicrogyria syndrome (MCAP); Congenital lipomatous overgrowth, vascular malformations, and epidermal nevi (CLOVE); Cowden syndrome 5 (CWS5)

Protein Families

PI3/PI4-kinase family

Database Links

HGNC: 8975

OMIM: 114480

KEGG: hsa:5290

STRING: 9606.ENSP00000263967

UniGene: Hs.553498

Message

Product >> Product Name：
Product >> Code：
Name： *
Email： *
Company/Organization：
Phone：
Since emails may get flagged by spam filters occasionally, we recommend leaving your phone number as a precaution. Your information is safe with us.
Question/Comment： *
Your Region： *
I'd like to receive email newsletters from Cusabio

Yes

No
How do you know CUSABIO?

Email

Distributor

Search engine

Advertisement

Others
CAPTCHA verification：
Please enter the characters shown. Click the image to refresh if unclear.

Code	CSB-RA578819A0HU
Size	US$210
	Order now
Image	Western Blot Positive WB detected in: Jurkat whole cell lysate, HepG2 whole cell lysate, Hela whole cell lysate, NIH/3T3 whole cell lysate, K562 whole cell lysate, 293 whole cell lysate, MCF-7 whole cell lysate All lanes: PIK3CA antibody at 1:1500 Secondary Goat polyclonal to rabbit IgG at 1/50000 dilution Predicted band size: 125 kDa Observed band size: 110 kDa Immunofluorescence staining of Hela Cells with CSB-RA578819A0HU at 1:50, counter-stained with DAPI. The cells were fixed in 4% formaldehyde, permeated by 0.2% TritonX-100, and blocked in 10% normal Goat Serum. The cells were then incubated with the antibody overnight at 4℃. Nuclear DNA was labeled in blue with DAPI. The secondary antibody was FITC-conjugated AffiniPure Goat Anti-Rabbit IgG (H+L).
Have Questions?	Leave a Message or Start an on-line Chat

PIK3CA Recombinant Monoclonal Antibody

Product Details

Related Products

Customer Reviews and Q&A

Target Background